Unmet needs in developing nanoparticles for precision medicine.

[1]  P. Aguiar,et al.  The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. , 2016, Immunotherapy.

[2]  Kwangmeyung Kim,et al.  Early diagnosis of arthritis in mice with collagen-induced arthritis, using a fluorogenic matrix metalloproteinase 3-specific polymeric probe. , 2011, Arthritis and rheumatism.

[3]  I. Kwon,et al.  Theranostic nanoparticles for future personalized medicine. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[4]  N. Jamieson,et al.  nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial , 2015 .

[5]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  N. Svrzikapa,et al.  First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. , 2013, Cancer discovery.

[7]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[8]  Grace Hu,et al.  Molecular MR imaging of melanoma angiogenesis with ανβ3‐targeted paramagnetic nanoparticles , 2005, Magnetic resonance in medicine.

[9]  N. Hadipour,et al.  Understanding the nanoparticle-protein corona complexes using computational and experimental methods. , 2016, The international journal of biochemistry & cell biology.

[10]  S. Lai,et al.  Anti-PEG immunity: emergence, characteristics, and unaddressed questions. , 2015, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[11]  A. Salvati,et al.  Balancing the effect of corona on therapeutic efficacy and macrophage uptake of lipid nanocapsules. , 2015, Biomaterials.

[12]  D. Arango,et al.  Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[13]  F. Atyabi,et al.  MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery. , 2014, International journal of pharmaceutics.

[14]  W. Mark Saltzman,et al.  A holistic approach to targeting disease with polymeric nanoparticles , 2015, Nature Reviews Drug Discovery.

[15]  R. Valkema,et al.  Tumor imaging and therapy using radiolabeled somatostatin analogues. , 2009, Accounts of chemical research.

[16]  M. Mahmoudi,et al.  Bypassing Protein Corona Issue on Active Targeting: Zwitterionic Coatings Dictate Specific Interactions of Targeting Moieties and Cell Receptors. , 2016, ACS applied materials & interfaces.

[17]  A. J. Tavares,et al.  Analysis of nanoparticle delivery to tumours , 2016 .

[18]  A. Schneeweiss,et al.  Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. , 2016, The Lancet. Oncology.